Drugs / Autologous Muscle Progenitor Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01953315 | Jan 2014 → Jan 2018 | disorder of neck of urinary bladder | Wake Forest University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Muscle Progenitor Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01953315 ↗ |
| Known as | MPCs | “The product, composed of autologous, ex vivo-expanded muscle progenitor cells (MPCs) in suspension, will be delivered via targeted injection into the bladder neck sphincter...” NCT01953315 ↗ |
| Modality | Cell therapy | “The product, composed of autologous, ex vivo-expanded muscle progenitor cells (MPCs) in suspension” NCT01953315 ↗ |
| Route | Other | “delivered via targeted injection into the bladder neck sphincter region” NCT01953315 ↗ |